The Impact of Advancing Age on Recurrence and Survival Following Major Hepatectomy for Colorectal Liver Metastases

Journal of Gastrointestinal Surgery

Volumn 21, Issue 2, 2017, Pages 266-274

  Bell, Richard ^a   Pandanaboyana, Sanjay ^b,c   Nisar, Saira ^a   Upasani, Vivek ^a   Toogood, Giles ^a   Lodge, J Peter ^a   Prasad, K Raj ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Age; Colorectal liver metastases; Elderly; Major hepatectomy

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; AGED; COLORECTAL TUMOR; ETIOLOGY; FEMALE; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; SURVIVAL ANALYSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 84992096781     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-016-3296-7     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10–29.
2. Taylor I. Liver metastases from colorectal cancer: lessons from past and present clinical studies. Br J Surg. 1996; 83. 456–460.
3. Morris EJA, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010; 97: 1110–1118.
4. Rees M, Tekkis PP, Welsh FKS et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008; 247, 125–135.
5. National Cancer Intelligence Network (2011) NHS Treated Cancer Patients Receiving Major Surgical Resections. National Cancer Intelligence Network, London.
6. Zacharias T, Jaeck D, Oussoultzoglou E et al. First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg. 2004; 240: 858–865.
7. Petrowsky H, Clavien PA. Should we deny surgery for malignant hepato-pancreatico-biliary tumors to elderly patients? World J Surg. 2005. 29: 1093–1100
8. Kulik U, Framke T, Grosshennig A et al. Liver resection of colorectal liver metastases in elderly patients. World J Surg. 2011; 35: 2063–2072.
9. Schmidt T, Strowitzki MJ, Reissfelder C et al. Influence of age on resection of colorectal liver metastases. J Surg Oncol. 2015 Jan 16. doi: 10.1002/jso.23872
10. Adam R, Frilling A, Elias D et al. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010. 97(3): 366-376.
11. Talarico L, Chen G, Pazdur R. Enrolment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004; 22: 4626–4631.
12. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004. 240 (2): 205-213
13. Cannon RM, Martin RC, Callender GG et al. Safety and efficacy of hepatectomy for colorectal metastases in the elderly. J Surg Oncol. 2011.104(7): 804-808
14. Mann CD, Neal CP, Pattenden CJ et al. Major resection of hepatic colorectal liver metastases in elderly patients - an aggressive approach is justified. Eur J Surg Oncol. 2008. 34(4): 428-432
15. Menon KV, Al-Mukhtar A, Aldouri A et al. Outcomes after major hepatectomy in elderly patients. J Am Coll Surg. 2006. 203(5): 677-683.
16. Cook EJ, Welsh FK, Chandrakumaran K et al. Resection of colorectal liver metastases in the elderly: does age matter? Colorectal Dis. 2012. 14(10): 1210-1216
17. Nojiri K, Nagano Y, Tanaka K et al. Validity of hepatic resection of colorectal liver metastases in the elderly (75 years and older). Anticancer Res. 2009. 29(2): 583-588
18. Reddy SK, Barbas AS, Turley RS et al. Major liver resection in elderly patients: a multi-institutional analysis. J Am Coll Surg. 2011. 212(5): 787-795.
19. Kenis C, Decoster L, Van Puyvelde K et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol. 2014. 32; 1; 19-26.
20. Soubeyran P, Bellera C, Goyard J et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One. 2014. 9 (12): e115060
21. Cauchy F, Aussilhou B, Dokmak S, et al.: Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg. 2012. 256:746-752
22. Evrard, Poston, Kissmeyer-Nielsen, et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One. 2014 Dec 8;9(12):e114404. doi: 10.1371/journal.pone.0114404
23. Wynne HA, Cope LH, Mutch E, et al.: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989. 9: 297–301.
24. Sastre J, Pallardo FV, Pla R, et al. Aging of the liver: Age associated mitochondrial damage in intact hepatocytes. Hepatology. 1996. 24: 1199–1205.
25. Muller-Hocker J, Aust D, Rohrbach H, et al. Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Hepatology. 1997. 26: 709–719.
26. Schmucker DL, Sanchez H. Liver regeneration and aging: A current perspective. Curr Gerontology and Ger Res. 2011;2011: 526379. doi: 10.1155/2011/526379
27. Sturesson C, Nilsson J, Eriksson S et al. Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB. 2013. 15, 646–652
28. Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350:2343–2351
29. O’Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997. 15(1): 246–250.
30. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009. 27(19):3109–3116.
31. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008 Mar 22; 371(9617): 1007–1016
32. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006. 24: 4976–4982.
33. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26: 4906–4911.
34. Hirokawa F, Hayashi M, Miyamoto Y et al. Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy. Ann Surg Oncol. 2014. 21(1):139-46.
35. Rahbari NN, Reissfelder C, Schulze-Bergkamen H et al. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer. 2014 Mar 11;14:174
36. Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB. 2013. 15(2): 106-115